Australian (ASX) Stock Market Forum

OCC - Orthocell Limited

Jump to new
Income from Striate+ and Remplir sales now being received.

Two newly elected high profile Non Executive Directors in Professor Fiona Woods and Kim Beasley should improve the companies recognition in international markets.
 
Still slowly developing.

I would have liked one of their treatment (awaiting approval) when I was younger - a non-surgical treatment for tennis elbow.
 
Chart update only.

1709190404627.png
 
access said:
Income from Striate+ and Remplir sales now being received.

Two newly elected high profile Non Executive Directors in Professor Fiona Woods and Kim Beasley should improve the companies recognition in international markets.
Click to expand...
Kim Beasley.
.. is there an emoji that is appropriate?
 
I would expect Kim is on the Board to draw on experience and connections from his days as Australian Ambassador in America from 2010 to 2016. Would have a lot of connections and understanding of how business works in American.

Remplir could be approved in America at the end of this year.
 
April update: Qrtly report. Increasing revenue of 1.61M in Q3 (+19% Q3-23).
Completes $3.5M placement, holds $20M cash.

Results of Remplir US market authorisation study to be released Q3 - 24.

Chart perspective, price remains in sideways range that's lasted 2.5yrs.
 
Continuing to expand with new registration applications and extending approval applications for existing products into new markets worldwide
 
Of OCC's 7 products, 2 are on the market and another one is expected to be released next year.

Petra Capital this month have a Target Price of $1.28 (current price .425 cents).
 
Institutions are now starting to notice OCC. Company put to the market a placement for $12 million at .60 cents but the offer was oversubscribed by another $5 million to $17 million.

Company now has cash of $35 million to fund release of Remplir in the USA and other countries around the world.
 
Had a convulsion in October followed by a retrace to around 60c.
Consolidation at that level and volume drop off.
Yesterday another surge with massive volume, and I entered at 75c level.
 

Attachments

  • OCC 2024-11-28 .jpg
    OCC 2024-11-28 .jpg
    103.4 KB · Views: 6
Sold into the strength over the past week, leaving only 15% to run, trailing stop in at 1.20
 

Attachments

  • OCC 2024-12-18 .jpg
    OCC 2024-12-18 .jpg
    114.5 KB · Views: 4
bk1 said:
Sold into the strength over the past week, leaving only 15% to run, trailing stop in at 1.20
Click to expand...
been a good run
Screenshot_20250108_092048_CommSec~2.jpg

.
Third Consecutive Quarter of Record Revenue as Strong Growth Continues​
• Orthocell’s rapid market penetration continues with the achievement of a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter.
• Revenue is up 9% on the previous record of $2.03 million achieved in the September ‘24 Quarter, an impressive result given the December Quarter traditionally is seasonally lower.
• Revenue is up 46% on the previous corresponding December ‘23 Quarter of $1.51 million showing significant and sustained growth.
• Striate+™ is currently sold in the US, Canada, Europe, UK, Australia and New Zealand. Remplir is currently sold in Australia, New Zealand and in the month of December recorded its first sales in Singapore.
• Multiple new international markets are nearing regulatory approvals as Orthocell pushes ahead with its global commercialisation plans targeting a market opportunity worth circa US$4.5 billion in key markets.
• Of particular focus is the near-term FDA approval of Remplir™ in the US which is expected by March/April 2025 and will open up the significant US$1.6 billion USA nerve repair market opportunity.
• The Company remains well funded to continue its aggressive growth plans with circa $31 million in cash and an R&D rebate of approximately $3 million expected in the March Quarter.
 
Remplir and Striate+ alone have a market target of $4.5 billion when they get established. Yet OCC's third product, Ortho ACI, will be the next for US approval and the market for this product could equal the market of the first two together.
 
access said:
Remplir and Striate+ alone have a market target of $4.5 billion when they get established. Yet OCC's third product, Ortho ACI, will be the next for US approval and the market for this product could equal the market of the first two together.
Click to expand...
My stock pick for 2025. FDA approval for Remplir will send the share price through the roof.
 
Top